Novel Combination Therapy Boosts Bladder Cancer Survival

An international Phase 3 clinical trial has shown that a combination of enfortumab vedotin and pembrolizumab significantly improves survival rates and reduces cancer recurrence for patients with muscle-invasive bladder cancer. This new perioperative treatment approach, recently approved by the FDA, represents a major advancement in oncology. The findings were published in The New England Journal of Medicine.